Kalaris Therapeutics
KLRS
59 hedge funds and large institutions have $36.3M invested in Kalaris Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 31 reducing their positions, and 14 closing their positions.
7% more capital invested
Capital invested by funds: $33.9M → $36.3M (+$2.42M)
0.08% less ownership
Funds ownership: 1.77% → 1.69% (-0.08%)
17% less funds holding
Funds holding: 71 → 59 (-12)
84% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 31
86% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$1.07M |
| 2 |
AI
Acuitas Investments
Seattle,
Washington
|
+$64.5K |
| 3 |
Amundi
Paris,
France
|
+$34.6K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$2.82K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$4.77M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$724K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$219K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$212K |
| 5 |
PI
Pennant Investors
Summit,
New Jersey
|
-$156K |
KLRS Hedge Fund Activity: Q3 2024 in Review
59 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q3 2024, worth a combined $36.3M — up 7.1% from $33.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of KLRS and 2 opened new positions — a net loss of 12 holders — while 31 trimmed existing stakes and 5 added.
The largest buyer was Octagon Capital Advisors, adding an estimated $1.07M. The largest seller was Artal Group, exiting entirely with an estimated $4.77M sold.
- 59 institutional investors held Kalaris Therapeutics (KLRS) as of Q3 2024, down from 71 in Q2 2024.
- Funds reported $36.3M of Kalaris Therapeutics stock for Q3 2024, up 7.1% quarter-over-quarter.
- 2 funds opened new Kalaris Therapeutics positions in Q3 2024 and 14 closed out, a net change of -12 holders.
- The largest Kalaris Therapeutics buyer in Q3 2024 was Octagon Capital Advisors, an estimated $1.07M added.
- The largest Kalaris Therapeutics seller in Q3 2024 was Artal Group, an estimated $4.77M sold.
Based on aggregated 13F filings for Q3 2024.